Glycans related to the CA19-9 antigen are elevated in distinct subsets of pancreatic cancers and improve diagnostic accuracy over CA19-9.

Abstract

Background & AimsThe cancer antigen 19-9 (CA19-9) is the current best biomarker for pancreatic cancer, but it is not increased in approximately 25% of pancreatic cancer patients at a cut-off value that provides a 25% false-positive rate. We hypothesized that antigens related to the CA19-9 antigen, which is a glycan called sialyl-Lewis A (sLeA), are increased in distinct subsets of pancreatic cancers.MethodsWe profiled the levels of multiple glycans and mucin glycoforms in plasma from 200 subjects with either pancreatic cancer or benign pancreatic disease, and we validated selected findings in additional cohorts of 116 and 100 subjects, the latter run with the investigators blinded to diagnoses and including cancers that exclusively were early stage.ResultsWe found significant increases in 2 glycans: an isomer of sLeA called sialyl-Lewis X, present both in sulfated and nonsulfated forms, and the sialylated form of a marker for pluripotent stem cells, type 1 N-acetyl-lactosamine. The glycans performed as well as sLeA as individual markers and were increased in distinct groups of patients, resulting in a 3-marker panel that significantly improved upon any individual biomarker. The panel showed 85% sensitivity and 90% specificity in the combined discovery and validation cohorts, relative to 54% sensitivity and 86% specificity for sLeA; and it showed 80% sensitivity and 84% specificity in the independent test cohort, as opposed to 66% sensitivity and 72% specificity for sLeA.ConclusionsGlycans related to sLeA are increased in distinct subsets of pancreatic cancers and yield improved diagnostic accuracy compared with CA19-9.